Guangming Daily News (reporter Cui Xingyi) "This new technology will become a new heavy weapon for China to overcome liver cancer." A few days ago, the main knife team led by Dong Jiahong, academician of the Chinese Academy of Engineering and president of Beijing Tsinghua Changgeng Hospital, successfully implemented China's first case of licensed access yttrium [90Y] resin microspheres for the clinical treatment of liver cancer in Boao, Hainan, which marked a new international precision interventional treatment plan for the treatment of liver malignant tumors in China. Dong Jiahong said that through the doctor's accurate operation of yttrium [90Y] resin microspheres, the realization of reduced treatment or potential radical treatment of patients with middle and advanced liver cancer is a landmark advanced achievement in the history of liver cancer treatment in China.
"The yttrium [90Y] resin microsphere is like a precision-delivered 'super nuclear bomb' that can conquer a tumor." Dong Jiahong introduced that the treatment plan adopts the world's leading interventional technology, injects yttrium [90Y] resin microspheres into liver blood vessels, releases high-energy β radiation, can kill tumor cells instantaneously at close range, and has almost no impact on normal liver tissue and surrounding environment. At the same time, yttrium [90Y] resin microspheres are used alone or combined with other comprehensive treatment methods such as biology, immunity, and targeting, which will benefit the majority of patients with liver cancer.
It is understood that liver cancer is known as the "king of cancer", and the number of new cases of liver cancer in China reaches 400,000 every year, accounting for about 47.6% of the new cases of liver cancer in the world. Most patients are found to be in the middle and advanced stages, only 20% to 30% of liver cancer patients can be surgically removed, and the recurrence rate within 5 years is still as high as 60% to 70%. The surgery was performed on a 34-year-old male patient with a history of hepatitis B, who was clearly diagnosed as primary liver cancer through various examinations, which exceeded the criteria for liver transplantation in various liver cancers, and could not be routinely surgically removed because the reserved liver volume was less than 40%. After many discussions among experts, it was determined that yttrium [90Y] resin microsphere therapy was the best choice for patients.
"The operation smoothly injected yttrium [90Y] resin microspheres into the tumor, and the patient's vital signs were stable during the operation, and there were no adverse reactions. The entire operation was completed in less than an hour. In the future, the speed and efficiency of treatment will continue to increase, and the patient's treatment experience will be better optimized. Zhang Lin, deputy chief physician of the Department of Interventional Hepatobiliary of Beijing Tsinghua Changgeng Hospital, and Niu Huimin, director of the Department of Interventional Medicine of Hainan Cancer Hospital, introduced the operation.
Li Sijin, chairman of the Nuclear Medicine Branch of the Chinese Medical Association and president of Shanxi Medical University, told reporters that the eight ministries and commissions of the state jointly issued the "Medium- and Long-term Development Plan for Medical Isotopes (2021-2035)" in June this year, which is the first programmatic document released for nuclear technology in the field of medical and health applications in China, fully affirming the unique role of nuclear medicine in the early diagnosis of major diseases, the accurate removal of small lesions and reasonable diagnosis and treatment. As a global innovative radioisotope drug, the landing of yttrium [90Y] resin microspheres in Boao, Hainan is like an engine, which will start and accelerate the long-term development and profound changes of nuclear medicine in China.
Guangming Daily ( 08/13/2021)
Source: Guangming Network - Guangming Daily